PreludeDx Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
49
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5M
- Investors
-
5
PreludeDx General Information
Description
Developer of decision-making, actionable tools designed to detect early-stage breast cancer. The company's platform combines proteomic analysis with artificial intelligence to assess recurrence risk and predict radiation therapy benefits to personalize treatment decisions for breast cancer patients, enabling oncologists to tailor interventions, potentially reducing unnecessary treatments and associated side effects.
Contact Information
Website
www.preludedx.comCorporate Office
- 26051 Merit Circle
- Suite 103
- Laguna Hills, CA 92653
- United States
Corporate Office
- 26051 Merit Circle
- Suite 103
- Laguna Hills, CA 92653
- United States
PreludeDx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 06-Nov-2025 | $5M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 22-Mar-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series F) | 15-Feb-2022 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series E) | 09-Jan-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 27-Jul-2018 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 15-Mar-2017 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 15-Mar-2016 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2014 | $1.46M | $2.05M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 27-Jul-2011 | $2.05M | $2.05M | Completed | Startup |
PreludeDx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 256,870 | $0.001000 | 8% | $8.37 | $8.37 | 1x | $8.37 | 4.13% |
| Series A | 455,556 | $0.001000 | 8% | $4.5 | $4.5 | 1x | $4.5 | 7.32% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PreludeDx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PreludeDx Patents
PreludeDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025235080-A1 | Biosignatures for breast cancer treatment and methods of use therof | Pending | 12-Mar-2024 | ||
| WO-2025193627-A1 | Biosignatures for breast cancer treatment and methods of use therof | Pending | 12-Mar-2024 | ||
| AU-2024376918-A1 | Method of treating breast cancer using a breast cancer panel involving cd8, foxp3, and/or pd-1 markers | Pending | 07-Nov-2023 | ||
| EP-4805734-A1 | Method of treating breast cancer using a breast cancer panel involving cd8, foxp3, and/or pd-1 markers | Pending | 07-Nov-2023 | ||
| WO-2025101661-A1 | Method of treating breast cancer using a breast cancer panel involving cd8, foxp3, and/or pd-1 markers | Inactive | 07-Nov-2023 | A61P35/00 |
PreludeDx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PreludeDx Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| UCSF Innovation Ventures | Venture Capital | Minority | ||
| BlueStone Venture Partners | Venture Capital | Minority | ||
| Evidity Health Capital | Growth/Expansion | Minority | ||
| National Cancer Institute | Government | |||
| Fjord Ventures | Venture Capital | Minority |
PreludeDx Investments & Acquisitions (2)
PreludeDx’s most recent deal was a Merger/Acquisition with CynoGen for . The deal was made on 09-Apr-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CynoGen | 09-Apr-2015 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Trove (Oakland) | 25-Mar-2015 | Early Stage VC | Business/Productivity Software |
PreludeDx FAQs
-
When was PreludeDx founded?
PreludeDx was founded in 2009.
-
Where is PreludeDx headquartered?
PreludeDx is headquartered in Laguna Hills, CA.
-
What is the size of PreludeDx?
PreludeDx has 49 total employees.
-
What industry is PreludeDx in?
PreludeDx’s primary industry is Diagnostic Equipment.
-
Is PreludeDx a private or public company?
PreludeDx is a Private company.
-
What is PreludeDx’s current revenue?
The current revenue for PreludeDx is .
-
How much funding has PreludeDx raised over time?
PreludeDx has raised $63M.
-
Who are PreludeDx’s investors?
UCSF Innovation Ventures, BlueStone Venture Partners, Evidity Health Capital, National Cancer Institute, and Fjord Ventures have invested in PreludeDx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
